FPT AI Factory announced the buildout of its next-generation AI infrastructure, accelerated by NVIDIA HGX B300 systems. This marks a significant milestone in empowering AI developers and enterprises to advance AI innovation across the region with reasoning and agentic capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326685242/en/NVIDIA HGX B300 AI is shifting into a new phase where its true value will be defined by ho...

National Institute of Information and Communications Technology (NICT), Japan’s leading public research organization in information and communications technology, today announced that it will exhibit at Mobile World Congress (MWC) Barcelona 2026, taking place from March 2–5, 2026, at Hall 6, Stand F54. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260216620427/en/NICT BOOTH NICT’s presence highlights Japan’s leadership in Beyond 5G...

Musaffa, a leading fintech platform dedicated to Shariah-compliant investment research and Islamic Finance Education, recently announced the launch of its Global Halal Investment Platform. This new platform provides 600,000+ Muslim investors across 200+ countries with expanded access to US capital markets via regulated and scalable trading and investment infrastructure while embedding Shariah compliance directly into the investing experience. The launch is powered by Alpaca, a global leader in ...

NHOA Energy, global provider of utility-scale energy storage systems, has been awarded two new Battery Energy Storage System (BESS) projects in Italy by a leading independent platform in the renewables and energy transition sector, with a total MACSE-contracted capacity of about 600 MWh and a total power of 90 MW. The two projects, located in Campania and Sardinia, represent NHOA Energy’s first systems awarded under MACSE (Meccanismo di Approvvigionamento di Capacità di Stoccaggio Elettrico),...

Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) today announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) and granted Priority Review for rusfertide. Rusfertide is an investigational, first-in-class hepcidin mimetic peptide therapeutic for the treatment of adults with polycythemia vera (PV). The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year. In a...